Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P423 NF-kB as a prognostic marker of response to biologic therapy in children with IBD

ECCO'20 Vienna

Year: 2020
Authors:

T. Radigina1, A. Illarionov2, D. Kuptsova1, A. Potapov3, S. Petrichuk1, A.P. Fisenko1

1National Medical Research Center for Children’s Health, Laboratory of Experimental Immunology and Virology, Moscow, Russian Federation, 2Pediatrics and Rheumatology, Sechenov First Moscow State Medical University, Moscow, Russian Federation, 3Gastroenterology and Hepatology, National Medical Research Center for Children’s Health, Moscow, Russian Federation

P424 Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada

ECCO'20 Vienna

Year: 2020
Authors:

A. FISCHER1, M. Oppe2, S. Stypa1, V. Lukyanov3, I. Petrakis4

1Takeda Canada Inc., Patient Value and Access, Toronto, Canada, 2Axentiva Solutions, Pharmacoeconomic, Sta. Cruz de Tenerife, Spain, 3IQVIA, Real-World Insights, Amsterdam, The Netherlands, 4Takeda Inc., Payer Value and Patient Access, Boston, USA

P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2

ECCO'20 Vienna

Year: 2020
Authors:

F.S. Macaluso1, W. Fries2, A. Viola2, A. Centritto2, M. Cappello3, E. Giuffrida3, A.C. Privitera4, G. Piccillo4, A. Magnano5, E. Vinci5, R. Vassallo6, A. Trovatello7, N. Belluardo8, E. Giangreco8, S. Camilleri9, S. Garufi9, C. Bertolami10, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Grova1, A. Orlando1

1Sicilian Network for Inflammatory Bowel Disease (SN-IBD), 1Department of Medicine, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy, 2A.O.U. Policlinico ‘G. Martino’, Inflammatory bowel disease Unit, Messina, Italy, 3A.O.U. Policlinico ‘P. Giaccone’, Gastroenterology and Hepatology Unit, Palermo, Italy, 4A.O. ‘Cannizzaro’, Inflammatory Bowel Disease Unit, Catania, Italy, 5Gastroenterology Unit, A.O.U. Policlinico ‘Vittorio Emanuele’, Catania, Italy, 6Gastroenterology and Endoscopy Unit, A.O. ‘Buccheri La Ferla Fatebenefratelli’, Palermo, Italy, 7A.O. ‘Umberto I’, Surgery Unit, Siracusa, Italy, 8Gastroenterology Unit, A.O. ‘Guzzardi’,Vittoria, Italy, 9Gastroenterology Unit, A.O.O.R. ‘S. Elia- M. Raimondi’, Caltanissetta, Italy, 10Gastroenterology Unit, A.O.O.R. ‘Papardo Piemonte’, Messina, Italy

P426 In failure of non-optimised adalimumab (ADA) with therapeutic serum levels, a change in biotherapy class is greater than an intensification of ADA dose in IBD patients

ECCO'20 Vienna

Year: 2020
Authors:

X. Roblin1, C. genin1, N. williet1, P. veyrard1, G. boschetti2, A.E. berger3, B. flourie2, S. nancey2, S. Paul3

1Department of Gastroenterology and Hepatology- Inserm- CIC1408, CHU Saint Etienne - Hospital Nord, Saint-Priest en Jarez, France, 2Department of Gastroenterology and Hepatology, CHU Lyon sud, Lyon, France, 3CHU Saint Etienne - Hospital Nord, Immunology, Saint-Priest en Jarez, France

P427 A hybrid approach of handling missing data in inflammatory bowel disease (IBD) trials: results from VISIBLE 1 and VARSITY

ECCO'20 Vienna

Year: 2020
Authors:

J. Chen1, S. Hunter2, K. Kisfalvi3, R.A. Lirio4

1Takeda, Statistics and Quantitative Sciences, Cambridge, USA, 2Cytel, Biostatistics, Cambridge, USA, 3Takeda, Research and development- Global Clinical Sciences, Cambridge, USA, 4Takeda, Clinical Science, Cambridge, USA

P428 Oral mesalamine use in Crohn’s disease after implementation of the American College of Gastroenterology guidelines: a TARGET-IBD cohort study

ECCO'20 Vienna

Year: 2020
Authors:

N. Gupta1, B.E. Sands2, M. Regueiro3, M. Dubinsky4, D. Rubin5, J. Hanson6, F. Aberra7, M. Weiss8, S. Watkins9, D. Gazis10, M. Long11

1Atlanta Gastroenterology, Gastroenterology, Atlanta, USA, 2Icahn School of Medicine at Mount Sinai Medical Center, Dr Henry D. Janowitz Division of Gastroenterology, New York, USA, 3Cleveland Clinic, Gastroenterology- Hepatology and Nutrition, Cleveland, USA, 4Ichan School of Medicine- Mount Sinai Hospital, Pediatric GI and Nutrition, New York, USA, 5Gastroenterology, University of Chicago, Chicago, USA, 6Atrium Health, Gastroenterology and Hepatology, Charlotte, USA, 7Gastroenterology, University of Pennsylvania, Philadelphia, USA, 8Gastroenterology, Gastro Florida, Tampa, USA, 9TARGET PharmaSolutions, Scientific and Medical Affairs, Durham, USA, 10TARGET PharmaSolutions, Statistics, Durham, USA, 11Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, USA

P429 Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilisation in Singapore

ECCO'20 Vienna

Year: 2020
Authors:

J.Q. Yeo1, H.L. Wee1, H.H. Cheen2, A. WONG2, T.G. Lim2, W.F. Leong3, B. Chowbay3, E. Salazar4, H.H. Shim4, W.P.W. Chan4, S.C. Kong5, W.C. Ong2

1Department of Pharmacy- Faculty of Science, National University of Singapore, Singapore, Singapore, 2Department of Pharmacy, Singapore General Hospital, Singapore, Singapore, 3Clinical Pharmacology, Singhealth, Singapore, Singapore, 4Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore, 5Department of Gastroenterology and Hepatology, Sengkang General Hospital, Singapore, Singapore

P430 Feasibility and reliability of gastrointestinal ultrasound in pregnant inflammatory bowel disease patients

ECCO'20 Vienna

Year: 2020
Authors:

F. de Voogd1, H. Joshi2, E. Van Wassenaer1, G. D’Haens1, K. Gecse1

1Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands, 2Gastroenterology, Sir H N Reliance Hospital, Mumbai, India

P431 Vitamin D binding protein in the limelight: IBD-related inflammation and circulating levels of vitamin D binding protein, total, free and bioavailable 25-hydroxyvitamin D

ECCO'20 Vienna

Year: 2020
Authors:

A. Aksan1,2,3, K. Böttger2,4, N. Hein4, Y. Caicedo-Zea5, I. Diehl6, C. Schumann5, F.P. Armbruster7, J.M. Stein1,2,4

1J. W Goethe University, Institute of Pharmaceutical Chemistry, Frankfurt am Main, Germany, 2Interdisciplinary Crohn-Colitis Centre Rhein-Main, Clinical and Scientific Research, Frankfurt am Main, Germany, 3Justus-Liebig-Universität, Institute of Nutritional Science, Giessen, Germany, 4DGD Clinics Frankfurt-Sachsenhausen, Gastroenterology and Clinical Nutrition, Frankfurt/Main, Germany, 5Immundiagnostik AG, Vitamin D Research, Bensheim, Germany, 6Immundiagnostik AG, Immunoassays, Bensheim, Germany, 7Immundiagnostik AG, Managing Director, Bensheim, Germany

P432 Effects and safety of a colon-long absorbing budesonide product in patients with mild to moderate ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

D. Pigniczki, K. Szántó, M. Rutka, K. Farkas, A. Bálint, R. Bor, A. Fábián, Z. Szepes, T. Molnár

Department of Medicine I, University of Szeged, Szeged, Hungary

P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)

ECCO'20 Vienna

Year: 2020
Authors:

S. Hoque1, S. Boccaletti2, A. Puenpatom3, C. Brown2, C. Black3, J. Roberts4, I. Rajkovic4, G. Milligan4

1Gastroenterology, Barts Health NHS Trust, London, UK, 2Merck Sharp and Dohme Ltd., Outcomes Research, Hertfordshire, UK, 3Merck and Co.- Inc., Outcomes Research, New Jersey, USA, 4Adelphi Real World, Observational Research, Manchester, UK

P434 Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry

ECCO'20 Vienna

Year: 2020
Authors:

M. Chaparro1, A. Garre1, M. Iborra2, M. Barreiro-de Acosta3, M.J. Casanova1, L. De Castro4, A. Fernández-Clotet5, J. Hinojosa6, M. Boscá-Watts7, D. Busquets8, A. López-García9, R. Lorente10, N. Manceñido11, T. Martínez12, D. Monfort13, J.L. Pérez-Calle14, A. Villoria15, T. Angueira16, F. Bermejo17, A.Y. Carbajo18, D. Carpio19, C. González-Muñoza20, F. Gomollón21, J.M. Huguet22, M. Rivero23, E. Iglesias-Flores24, M. Sierra25, L. Hernández-Villalba26, E. Domènech27, J.P. Gisbert1

1Hospital Universitario de La Princesa- IIS-IP- Universidad Autónoma de Madrid and CIBEREHD, Servicio de Aparato Digestivo, Madrid, Spain, 2Hospital Universitario y Politécnico La Fe and CIBEREHD, Gastroenterology Unit, Valencia, Spain, 3Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 4Hospital Álvaro Cunqueiro-Complexo Hospitalario Universitario de Vigo, Gastroenterology Unit, Vigo, Spain, 5Hospital Clìnic, Gastroenterology Unit, Barcelona, Spain, 6Hospital de Manises, Gastroenterology Unit, Valencia, Spain, 7Hospital Clínico de Valencia. Universitat de València, Gastroenterology Unit, Valencia, Spain, 8Hospital Universitario de Girona Dr. Josep Trueta, Gastroenterology Unit, Gerona, Spain, 9Hospital del Mar and Institut Hospital del Mar d’Investigacions Mèdiques, Gastroenterology Unit, Barcelona, Spain, 10Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain, 11Hospital Infanta Sofía, Gastroenterology Unit, San Sebastián de los Reyes, Spain, 12Hospital Virgen de la Luz, Gastroenterology Unit, Cuenca, Spain, 13Consorci Sanitari de Terrasa, Gastroenterology Unit, Barcelona, Spain, 14Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain, 15Hospital de Sabadell. Depàrtament de Medicina. Universitat Autònoma de Barcelona y CIBEREHD, Gastroenterology Unit, Barcelona, Spain, 16Hospital General de Tomelloso and CIBEREHD, Gastroenterology Unit, Ciudad Real, Spain, 17Hospital Universitario Fuenlabrada and Instituto de Investigación Sanitaria del Hospital de La Paz IdiPAZ, Gastroenterology Unit, Madrid, Spain, 18Hospital Universitario Río Hortega, Gastroenterology Unit, Valladolid, Spain, 19Complexo Hospitalario Universitario de Pontevedra, Gastroenterology Unit, Pontevedra, Spain, 20Hospital de la Sta Creu i San Pau, Gastroenterology Unit, Barcelona, Spain, 21HCU Lozano BLesa- IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain, 22Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain, 23Hospital Universitario Márques de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain, 24Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 25Complejo Asistencial Universitario de León, Gastroenterology Unit, León, Spain, 26Hospital Santos Reyes, Gastroenterology Unit, Burgos, Spain, 27Hospital Universitario Germans Trials i Pujol and CIBEREHD, Gastroenterology Unit, Barcelona, Spain

P435 Real-world clinical outcomes after elective discontinuation of first-use biologics in IBD patients

ECCO'20 Vienna

Year: 2020
Authors:

U.N. Shivaji1, A. Bazarova2, T. Critchlow3, O.M. Nardone4, S.C. Smith4, M. Love3, J. Davis3, S. Ghosh1, M. Iacucci1

1Gastroenterology, NIHR Birmingham Biomedical Research Centre- University Hospitals Birmingham NHS Foundation Trust and University of Birmingham- UK, Birmingham, UK, 2Institute for Biological Physics, University of Cologne, Cologne, Germany, 3Gastroenterology, University Hospitals Birmingham- UK, Birmingham, UK, 4Gastroenterology, Institute of Immunology and Immunotherapy- University of Birmingham, Birmingham, UK

P436 Evaluation of targeted vitamin D supplementation regimen in postoperative patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

Y. LI, L. Zheng, D. Yao, Z. Zhou, B. Liu, Y. Huang, Y. Duan

Department of Surgery, Shanghai Ninth People’s Hospital -Shanghai Jiaotong University School, Shanghai, China

P437 Anti-TNF α antibodies in patients with inflammatory bowel disease naive to anti-TNF therapy treated with biosimilar infliximab (CT-P13): a prospective single-centre real-life study

ECCO'20 Vienna

Year: 2020
Authors:

R. Filip1, A. Pękala1, S. Jarmakiewicz-Czaja2

1Kliniczny Szpital Wojewodzki Nr 2 im. Sw. Krolowej Jadwigi w Rzeszowie, Klinika Gastroenterologii i Centralna Pracownia Endoskopii, Rzeszow, Poland, 2Institute of Health Sciences, Medical College of Rzeszow University, Rzeszow, Poland

P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study

ECCO'20 Vienna

Year: 2020
Authors:

B. Barberio1, F. Zingone1, A. Ferronato2, A. Buda3, P. Melatti1, A. Gubbiotti1, D. Massimi1, C. Casadei1, L. Cingolani4, E.V. Savarino1

1Department of Surgery- Oncology- Gastroenterology, University of Padua, Padua, Italy, 2Pedemontana- Santorso, Digestive Endoscopy Unit, Santorso, Italy, 3Gastroenterology Unit, Feltre Hospital, Santorso, Italy, 4Department of Surgery- Oncology- Gastroenterology, University of Padua, Paduaita, Italy

P439 Patient’ recruitment for a Phase 3 inflammatory bowel disease (IBD) programme is significantly increased when accessing the CT-SCOUT™ platform

ECCO'20 Vienna

Year: 2020
Authors:

Y. Bouhnik1, X. Roblin2, R. Mrad3, X. Hebuterne4, D. Laharie5, C. Tanasa Stefanescu1, S. Nancey6, A. Boureille7, A. Amiot8, N. Sebbah9, L. Peyrin Biroulet10

1Hopital Beaujon, Service de Gastroentérologie- MICI et Assistance Nutritive, Clichy, France, 2Hôpital Bellevue, Service de Gastroentérologie, Saint Etienne, France, 3CTMA, Project Manager, Paris, France, 4Hôpital de l’Archet, Service de Gastroentérologie et Nutrition Clinique, Nice, France, 5Hôpital Haut Lévêque, Service d’Hépato-gastroentérologie, Bordeaux, France, 6Hôpital Lyon Sud, Service d’Hépatogastroentérologie, Lyon, France, 7CHU Hôtel Dieu, Institut des maladies de l’appareil digestif, Nantes, France, 8Hôpital Henri Mondor, Service d’Hépato-Gastro-Entérologie, Creteil, France, 9CTMA, Chief Operating Officer, Paris, France, 10CHU Nancy, Service d’Hépato-gastroentérologie, Nancy, France

P440 Polimedication in patients with inflammatory bowel disease: prevalence and outcomes in a retrospective unicentric series

ECCO'20 Vienna

Year: 2020
Authors:

F. Mesonero Gismero, C. Fernández, E. Sánchez-Rodríguez, A. García-García de Paredes, A. Albillos, A. López-Sanromán

Department of Gastroenterology, Hospital Universitario Ramón y Cajal, Madrid, Spain

P441 Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis

ECCO'20 Vienna

Year: 2020
Authors:

J. Ollech1, I. Normatov2, S. Dwadasi2, S. Dalal2, D. Micic2, A. Israel2, J. Labas2, P. Joel2, R. Cohen2, D. Rubin2, S. Atsushi2

1Gastroenterology, Rabin Medical Center- University of Chicago Medicine, Petach Tikva, Israel, 2Gastroenterology, University of Chicago Medicine, Chicago, USA

P442 Long-term quality of life after surgery for perianal Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

I. Angriman, M. Tomassi, G. Bordignon, R. Bardini, C. Ruffolo, M. Scarpa

Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy